GSK Reports the NMPA’s NDA Acceptance with Priority Review of Linerixibat for Cholestatic Pruritus

Why It Matters

Priority review in China accelerates market entry for a therapy addressing a high‑unmet‑need symptom in PBC, potentially expanding GSK’s revenue streams and strengthening its hepatology portfolio.

Key Takeaways

• NMPA grants priority review for linerixibat in China
• Phase III GLISTEN trial met primary endpoints
• Itch relief achieved rapidly with sustained effect
• Review ongoing in US, EU, UK, Canada
• Potential first-in-class IBAT inhibitor for PBC itch

Pulse Analysis

China’s fast‑track regulatory pathway signals a strategic push by GSK to capture a sizable market for cholestatic pruritus, a symptom that severely impacts quality of life for PBC patients. The NMPA’s priority review not only shortens the approval timeline but also positions GSK ahead of competitors seeking footholds in the growing Chinese hepatology sector, where demand for innovative itch‑relief solutions is rising sharply.

The GLISTEN Phase III trial, enrolling patients with moderate‑to‑severe pruritus, met its primary and secondary endpoints, showing that a 40 mg dose of linerixibat delivers rapid itch reduction and improves sleep continuity. As an ileal bile acid transporter (IBAT) inhibitor, linerixibat reduces bile acid accumulation—a key driver of cholestatic itch—offering a mechanistic advantage over symptomatic antihistamines. These robust efficacy signals, presented at EASL 2025, reinforce the drug’s potential as a disease‑modifying option rather than a mere palliative.

Beyond China, GSK’s parallel submissions in the US, EU, UK and Canada suggest a coordinated global launch strategy. If approved, linerixibat could become the first IBAT inhibitor marketed for PBC‑related pruritus, differentiating GSK’s hepatology pipeline and opening cross‑border reimbursement opportunities. The move also aligns with broader industry trends toward targeting bile‑acid pathways, potentially prompting competitors to accelerate similar programs. Successful commercialization would not only address an unmet clinical need but also contribute materially to GSK’s earnings outlook in the specialty pharma segment.